Escitalopram for Agitation in Alzheimer's Disease


Agitation is common in Alzheimer's disease (AD), but current indicated medications are associated with risks. There is need for safer yet still effective approaches to manage agitation in AD. The S-CitAD study enrols participants with AD, who have developed verbal or physical agitation or increased purposeless movements that cause distress to the participant and/or their loved ones. Participants will be initially provided a non-medication management approach for agitation, and if this is ineffective, will be considered for treatment with a medication for 12 weeks.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 99

Inclusion criteria:

1. Diagnosis of Alzheimer's disease
2. Moderate to severe agitation
3. Has a family member that knows them and can attend visits

Exclusion criteria:

1. No neurological or psychiatric disorders that may interfere with treatment
2. Residence in a long term acute care facility


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Ramnik Sekhon

Principal investigator:

Zahinoor Ismail

Clinical trial: